Oxybutynin, a common drug to manage overactive bladder, may help alleviate hot flash symptoms among men receiving androgen ...
An individual-patient meta-analysis sheds light on the optimal duration of androgen deprivation therapy in men with prostate cancer on definitive radiotherapy.
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...
Men with prostate cancer who get hormone therapy experience hot flashes, where they experience intense and sudden heat and ...
—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...
Chinese NMPA approves Bayer’s oral ARi Nubeqa in combo with ADT for use in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, February 4, 2026, 14:00 ...
Short-term androgen deprivation combined with high-dose radiation therapy aids oncologic control in localized prostate cancer. In patients with intermediate- or high-risk localized prostate cancer, ...
PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...
Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...